Chief Medical Officer

Dr. Cedarbaum serves as our acting Chief Medical Officer. Dr. Cedarbaum is a neurologist/clinical trialist with sub-specialty in Movement Disorders. He has spent the majority of his career as an executive in the pharmaceutical industry, leading teams in the areas of neurodegenerative, neuropsychiatric and retinal disorders at Regeneron, Elan, Cytokinetics and Bristol-Myers Squibb and Biogen. His research activities have encompassed efforts to develop novel clinical outcome measures and biomarkers, including digital health technologies for clinical trials.  He has served as chair of the ADNI Private Partner Scientific Board, the Industry Scientific Advisory Board of the Michael J. Fox Foundation-sponsored Parkinson Progression Markers Initiative, and as industry co-chair of the Critical Path for Parkinson’s consortium.  He has authored or-co-authored over 120 peer-reviewed papers and book chapters. Dr. Cedarbaum currently holds appointments in the departments of Neurology and Psychiatry at Yale Medical School.